惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

C
Check Point Blog
罗
罗磊的独立博客
量
量子位
Microsoft Azure Blog
Microsoft Azure Blog
钛媒体：引领未来商业与生活新知
钛媒体：引领未来商业与生活新知
J
Java Code Geeks
M
MIT News - Artificial intelligence
月光博客
月光博客
IT之家
IT之家
D
DataBreaches.Net
A
About on SuperTechFans
博
博客园 - 三生石上(FineUI控件)
Cyber Security Advisories - MS-ISAC
Cyber Security Advisories - MS-ISAC
Last Week in AI
Last Week in AI
D
Docker
The GitHub Blog
The GitHub Blog
B
Blog
V
Visual Studio Blog
博
博客园 - Franky
N
Netflix TechBlog - Medium
博
博客园 - 【当耐特】
Martin Fowler
Martin Fowler
博
博客园 - 聂微东
U
Unit 42

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2026 Earnings Call ...
2026-05-07 · via All Articles on Seeking Alpha

Mirum Pharmaceuticals, Inc. (MIRM) Q1 2026 Earnings Call May 6, 2026 4:30 PM EDT

Company Participants

Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations
Christopher Peetz - CEO & Director
Peter Radovich - COO & President
Eric Bjerkholt - Chief Financial Officer
Joanne M. Quan - Chief Medical Officer

Conference Call Participants

Yesha Patel - Evercore ISI Institutional Equities, Research Division
Joshua Schimmer - Cantor Fitzgerald & Co., Research Division
Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division
Rohit Bhasin - Morgan Stanley, Research Division
James Condulis - Stifel, Nicolaus & Company, Incorporated, Research Division
Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division
Lisa Walter - RBC Capital Markets, Research Division
Jessica Fye - JPMorgan Chase & Co, Research Division
Ryan Mcelroy - Leerink Partners LLC, Research Division
Ryan Deschner - Raymond James & Associates, Inc., Research Division
Joseph Thome - TD Cowen, Research Division
Charles Wallace - H.C. Wainwright & Co, LLC, Research Division

Presentation

Operator

Good afternoon, and welcome to Mirum Pharmaceuticals First Quarter 2026 Earnings Conference Call. My name is Tracy, and I will be your operator today. [Operator Instructions]

I would now like to hand the call -- the conference over to Andrew McKibben, SVP of Strategic Finance and Investor Relations. Please go ahead.

Andrew McKibben
Senior Vice President, Strategic Finance & Investor Relations

Thank you, Tracy, and good afternoon, everyone. I'd like to welcome you to Mirum Pharmaceuticals First Quarter 2026 Earnings Conference Call. For our prepared remarks, I'm joined today by our Chief Executive Officer, Chris Peetz; our President and Chief Operating Officer, Peter Radovich; and Eric Bjerkholt, our Chief Financial Officer. Our Chief Medical Officer, Joanne Quan, will be joining us for Q&A.

Earlier this afternoon, Mirum issued a press release reporting our first quarter 2026 financial results. Copies of the press release and our SEC filings are available on the

此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。